Serum Institute of India (SII) CEO Adar Poonawalla has applied to Drugs Controller General of India (DGCI) seeking emergency use authorization for its COVID-19 vaccine ‘Covishield’ in the country.
Poonawalla broke the news on Twitter and said, “As promised, before the end of 2020, @SerumInstIndia has applied for emergency use authorization for the first made-in-India vaccine, COVISHIELD. This will save countless lives, and I thank the Government of India and [email protected] for their invaluable support.”
As promised, before the end of 2020, @SerumInstIndia has applied for emergency use authorisation for the first made-in-India vaccine, COVISHIELD. This will save countless lives, and I thank the Government of India and Sri @narendramodi ji for their invaluable support.
— Adar Poonawalla (@adarpoonawalla) December 7, 2020
With this, SII also became the first indigenous company to apply to the DCGI seeking approval for the vaccine developed along with global pharma giant AstraZeneca and Oxford University.
After Prime Minister Narendra Modi visited the company’s facility in Pune recently, Adar Poonawalla had said that indications suggest that Centre may purchase 300-400 million doses by July 2021.
He further said the SII has already produced 40-50 million doses of the vaccine per month, and the pharma giant is planning to stretch it up to 100 million doses of the vaccine per month by February.
Earlier, Pfizer sought emergency-use authorization for its COVID-19 vaccine in India. Pfizer India has become the first pharma company to seek an emergency-use authorization for its coronavirus vaccine in the country from DCGI.
The United Kingdom and Bahrain have allowed the emergency use of the Pfizer COVID-19 vaccine. In total, Britain has ordered 40 million doses – enough to vaccinate 20 million people in the country of 67 million. About 800,000 doses are expected to be available within the first week. Initial doses that have arrived from Belgium are being stored in secure locations across the country.